3 news items
Should You Hold Viking Therapeutics in Your Portfolio?
AMGN
LLY
NVO
15 May 24
phase III program on the candidate across obesity, obesity-related conditions and diabetes.
Despite the intense competition, the obesity
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
LLY
30 Apr 24
regulatory approvals; the impact and uncertain outcome of acquisitions and business development transactions and related costs; intense competition affecting
Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off'
LLY
NVDA
NVO
5 Mar 24
to the intense
- Prev
- 1
- Next